| Biological synthesis of metallic nanoparticles KN Thakkar, SS Mhatre, RY Parikh Nanomedicine: nanotechnology, biology and medicine 6 (2), 257-262, 2010 | 2815 | 2010 |
| The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor Y Xiao, KN Thakkar, H Zhao, J Broughton, Y Li, JA Seoane, AN Diep, ... Proceedings of the National Academy of Sciences 117 (35), 21441-21449, 2020 | 78 | 2020 |
| The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling EJ Moon, SS Mello, CG Li, JT Chi, K Thakkar, JG Kirkland, EL Lagory, ... Nature communications 12 (1), 4308, 2021 | 59 | 2021 |
| TRIM24 links glucose metabolism with transformation of human mammary epithelial cells TN Pathiraja, KN Thakkar, S Jiang, S Stratton, Z Liu, M Gagea, X Shi, ... Oncogene 34 (22), 2836-2845, 2015 | 56 | 2015 |
| Regulation of gene expression in human cancers by TRIM24 S Appikonda, KN Thakkar, MC Barton Drug Discovery Today: Technologies 19, 57-63, 2016 | 48 | 2016 |
| Neutralization of PD-L2 is essential for overcoming immune checkpoint blockade resistance in ovarian cancer YR Miao, KN Thakkar, J Qian, MS Kariolis, W Huang, S Nandagopal, ... Clinical cancer research 27 (15), 4435-4448, 2021 | 46 | 2021 |
| Generation of stable expression mammalian cell lines using lentivirus N Tandon, KN Thakkar, EL LaGory, Y Liu, AJ Giaccia Bio-protocol 8 (21), e3073-e3073, 2018 | 44 | 2018 |
| Biological synthesis of metallic nanoparticles N Thakkar Kaushik, S Mhatre Snehit, Y Parikh Rasesh Nanomedicine: Nanotechnology and Biology and Medicine 6, 257-262, 2010 | 30 | 2010 |
| Cross-talk between chromatin acetylation and SUMOylation of tripartite motif–containing protein 24 (TRIM24) impacts cell adhesion S Appikonda, KN Thakkar, PK Shah, SYR Dent, JN Andersen, MC Barton Journal of Biological Chemistry 293 (19), 7476-7485, 2018 | 28 | 2018 |
| Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination–deficient cancer models M Mehibel, Y Xu, CG Li, EJ Moon, KN Thakkar, AN Diep, RK Kim, ... The Journal of clinical investigation 131 (11), 2021 | 19 | 2021 |
| Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma YR Miao, K Thakkar, C Cenik, D Jiang, K Mizuno, C Jia, CG Li, H Zhao, ... Journal of Experimental Medicine 219 (9), e20220214, 2022 | 7 | 2022 |
| Tissue-specific metabolism and TRIM24 KN Thakkar, SA Stratton, MC Barton Aging (Albany NY) 7 (10), 736, 2015 | 3 | 2015 |
| Neutralizing PD-L1 and PD-L2 Enhances the Efficacy of Immune Checkpoint Inhibitors in Ovarian Cancer AJG Yu Miao, Kaushik N. Thakkar, Jin Qian, Mihalis S. Kariolis, Huang Wei ... bioRxiV, 2020 | 2 | 2020 |
| Modulating the tumor microenvironment to enhance efficacy of PARP inhibitors. M Mehibel, J Xu, A Diep, K Thakkar, CG Li, Y Xiao, E Rankin, A Giaccia Journal of Clinical Oncology 37 (15_suppl), e14715-e14715, 2019 | 2 | 2019 |
| Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade YR Miao, KN Thakkar, J Qian, MS Kariolis, W Huang, N Saravanan, ... Oncol 152 (2), 243-50, 2019 | 1 | 2019 |
| sPD-1 VARIANT–FC FUSION PROTEINS AJ Giaccia, TA Aguilera, MS Kariolis, Y Miao, K Thakkar, XE Zhang US Patent App. 17/962,983, 2023 | | 2023 |
| SPD-1 variant# FC fusion proteins AJ Giaccia, TA Aguilera, MS Kariolis, Y Miao, K Thakkar, XE Zhang US Patent 11,498,955, 2022 | | 2022 |
| Abstract IA-003: Oxygen dependent resistance to PARP inhibitors M Mehibel, J Xu, G Li, J Moon, K Thakkar, A Diep, R Kim, J Bloomstein, ... Clinical Cancer Research 27 (8_Supplement), IA-003-IA-003, 2021 | | 2021 |
| Reading histone modifications, an oncoprotein is modified in return News-Article https://bit.ly/2KKaJdM https://bit.ly/2GGEOZb https://bit.ly/2KOVoc3 https …, 2018 | | 2018 |
| TRIM24 orchestrates metabolic reprogramming and EMT in Breast Cancer K Thakkar | | 2016 |
Rasesh ParikhScientist, Medical University of South Carolina在 musc.edu 的电子邮件经过验证
